Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Diogo Martins-Branco"'
Autor:
Filipa Alves da Costa, Fábio Cardoso Borges, Adriana Ramos, Alexandra Mayer, Claudia Brito, Catarina Ramos, Catarina Bernardo, Mariane Cossito, Cláudia Furtado, Arlindo R. Ferreira, Diogo Martins-Branco, Ana da Costa Miranda, António Lourenço
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-11 (2023)
Abstract Background New drugs for locally advanced or metastatic breast cancer have led to clinical benefits, aside with increasing costs to healthcare systems. The current financing model for health technology assessment (HTA) privileges real-world
Externí odkaz:
https://doaj.org/article/e2e767a1400a49738acd66aac0de102f
Autor:
Guilherme Nader-Marta, Chiara Molinelli, Véronique Debien, Diogo Martins-Branco, Philippe Aftimos, Evandro de Azambuja, Ahmad Awada
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Antibody–drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB) targeting a specific target antigen, a cytotoxic payload, and a linker binding the antibody to th
Externí odkaz:
https://doaj.org/article/7a5ff39dd5c6423c93c2492ba0e8da2b
Autor:
Diogo Martins-Branco, Sofia Cristóvão Ferreira, Emanuel Gouveia, Saudade André, Susana Esteves, Margarida Brito, António Moreira
Publikováno v:
Acta Médica Portuguesa (2023)
Introduction: Genomic assays are useful tools for tailoring adjuvant treatment in early breast cancer. We aimed to analyse the role of an institutional protocol of a genomic assay for chemotherapy de-escalation. Material and Methods: Prospective coho
Externí odkaz:
https://doaj.org/article/c99997e8e5fe434e83f8ad0b17c2a187
Autor:
Fábio Cardoso Borges, Filipa Alves da Costa, Adriana Ramos, Catarina Ramos, Catarina Bernardo, Cláudia Brito, Alexandra Mayer-da-Silva, Cláudia Furtado, Arlindo R. Ferreira, Diogo Martins-Branco, Ana Miranda, António Lourenço
Publikováno v:
Breast, Vol 62, Iss , Pp 135-143 (2022)
Background: Real-world (RW) data may provide valuable information on the effectiveness and safety of medicines, which is particularly relevant for clinicians, patients and third-party payers. Evidence on the effectiveness of palbociclib plus fulvestr
Externí odkaz:
https://doaj.org/article/181af1dd6dce41e2a1893c95719d02c0
Autor:
Ana Monteiro, Emanuel Gouveia, Daniela Garcez, Sara Donato, Diogo Martins-Branco, Joana Marques, Hugo Nunes, Maria José Passos, Ana Isabel Clara, António Moreira
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 2, Pp 501-507 (2020)
Merkel cell carcinoma is a rare and aggressive cutaneous tumor, and the use of checkpoint inhibitors immunotherapy is a recent indication in its metastatic setting, both first and second line. However, the widespread use of immunotherapy is associate
Externí odkaz:
https://doaj.org/article/0a0c8a0a52e2460eb34b2f212c3c0408
Autor:
Gabriela Sousa, Barbara Gomes, Diogo Martins-Branco, Silvia Lopes, Rita Canario, Joao Freire, Madalena Feio, Jose Ferraz-Goncalves
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Introduction There is growing concern about the aggressiveness of cancer care at the end of life (ACCEoL), defined as overly aggressive treatments that compromise the quality of life at its end. Recognising the most affected patients is a cornerstone
Externí odkaz:
https://doaj.org/article/b8c8ed5e6b374dde8f91a9e04a70b437
Autor:
Soraia Lobo-Martins, Diogo Martins-Branco, Patrícia Miguel Semedo, Cecília Melo Alvim, Ana Maria Monteiro, Inês Vendrell, Emanuel Gouveia, Maria José Passos, Luís Costa, André Mansinho, Rita Teixeira de Sousa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/ecd48dd06f704e0f9737e40a934a58e4
Autor:
Diogo Martins-Branco, Chiara Molinelli, Guilherme Nader Marta, Lieveke Ameye, Marianne Paesmans, Roberto Salgado, Philippe Aftimos, Evandro de Azambuja
Publikováno v:
Cancer Research. 83:P1-07
Background: Neoadjuvant treatment allows to better distinguish responders from non-responders, and to tailor post-neoadjuvant treatment according to tumor response in patients with HER2+ and triple-negative early breast cancer. For HR+/HER2- tumors,
Autor:
Diogo Alpuim Costa, José Guilherme Gonçalves Nobre, João Paulo Fernandes, Marta Vaz Batista, Ana Simas, Carolina Sales, Helena Gouveia, Leonor Abreu Ribeiro, Andreia Coelho, Margarida Brito, Mariana Inácio, André Cruz, Mónica Mariano, Joana Savva-Bordalo, Ricardo Fernandes, André Oliveira, Andreia Chaves, Mário Fontes-Sousa, Mafalda Sampaio-Alves, Diogo Martins-Branco, Noémia Afonso
Publikováno v:
Oncology and Therapy. 10:225-240
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format
Autor:
Diogo Martins-Branco, Marie Kassapian, Véronique Debien, Rafael Caparica, Daniel Eiger, Urania Dafni, Charitini Andriakopoulou, Sarra El-Abed, Miguel Izquierdo, Malou Vicente, Saranya Chumsri, Martine Piccart-Gebhart, Alvaro Moreno-Aspitia, Ann Søegaard Knop, Janine Lombard, Evandro de Azambuja
Publikováno v:
Cancer Research. 82:P1-14
Background: The erythropoietin (EPO) receptor activation can stimulate tumor proliferation and may be implicated in resistance to anti-HER2 therapies. EPO administration can be used for the management of chemotherapy-induced anemia. We aim to assess